FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308599711> ?p ?o ?g. }

• W4308599711 endingPage "100603" @default.
• W4308599711 startingPage "100603" @default.
• W4308599711 abstract "•Most patients with BRAF-mutant mCRC received doublet chemotherapy with or without targeted therapy at first line.•The triplet chemotherapy + targeted therapy group had the highest ORR (52.5%) versus the other treatment groups.•Median PFS was 6.0 months (95% CI 5.3-6.7) and median OS was 12.9 months (95% CI 11.6-14.1) across all regimens.•About 52.5% of patients were able to receive a potentially effective second-line therapy.•This study highlights the unmet need for effective treatment strategies for patients with BRAF-mutant mCRC. BackgroundBRAFV600E mutations occur in 8%-12% of metastatic colorectal cancer (mCRC) cases and are associated with poor survival. European guidelines recommend combination (doublet or triplet) chemotherapy plus bevacizumab in first line. However, an unmet need remains for more effective treatments for these patients.Patients and methodsCAPSTAN CRC is a European, retrospective, multicenter, observational study evaluating real-world treatment practices for patients with BRAFV600E-mutant mCRC treated between 1 January 2016 and 31 January 2020. The primary objective was to describe first-line treatment patterns. Secondary objectives included describing baseline demographics, mutational testing procedures, treatment effectiveness, and safety.ResultsIn total, 255 patients (median age 66.0 years; 58.4% female) with BRAFV600E-mutant unresectable mCRC from seven countries were included. Most had right-sided tumors (52.5%) and presented with synchronous disease at diagnosis (66.4%). Chemotherapy plus targeted therapy (68.7%) was preferred at first line over chemotherapy alone (31.3%). The main first-line treatments were FOLFOX plus bevacizumab (27.1%) and FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan) with/without bevacizumab (27.1%/19.2%). Median duration of first-line treatment was 4.9 months. Overall, 52.5% received second-line treatment. Across all first-line regimens, progression-free survival (PFS) and overall survival were 6.0 [95% confidence interval (CI) 5.3-6.7] months and 12.9 (95% CI 11.6-14.1) months, respectively. Triplet plus targeted therapy was associated with more adverse events (75.0%) compared with triplet chemotherapy alone (50.0%) and doublet chemotherapy alone (36.1%). Multivariate analysis identified low body mass index and presence of three or more metastatic sites as significant prognostic factors for PFS.ConclusionsThis study is, to date, the largest real-world analysis of patients with BRAFV600E-mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients. The data highlight the intrinsic aggressiveness of this disease subgroup, confirming results from previous real-world studies and clinical trials, and stressing the urgent need for more effective treatment options in this setting. BRAFV600E mutations occur in 8%-12% of metastatic colorectal cancer (mCRC) cases and are associated with poor survival. European guidelines recommend combination (doublet or triplet) chemotherapy plus bevacizumab in first line. However, an unmet need remains for more effective treatments for these patients. CAPSTAN CRC is a European, retrospective, multicenter, observational study evaluating real-world treatment practices for patients with BRAFV600E-mutant mCRC treated between 1 January 2016 and 31 January 2020. The primary objective was to describe first-line treatment patterns. Secondary objectives included describing baseline demographics, mutational testing procedures, treatment effectiveness, and safety. In total, 255 patients (median age 66.0 years; 58.4% female) with BRAFV600E-mutant unresectable mCRC from seven countries were included. Most had right-sided tumors (52.5%) and presented with synchronous disease at diagnosis (66.4%). Chemotherapy plus targeted therapy (68.7%) was preferred at first line over chemotherapy alone (31.3%). The main first-line treatments were FOLFOX plus bevacizumab (27.1%) and FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan) with/without bevacizumab (27.1%/19.2%). Median duration of first-line treatment was 4.9 months. Overall, 52.5% received second-line treatment. Across all first-line regimens, progression-free survival (PFS) and overall survival were 6.0 [95% confidence interval (CI) 5.3-6.7] months and 12.9 (95% CI 11.6-14.1) months, respectively. Triplet plus targeted therapy was associated with more adverse events (75.0%) compared with triplet chemotherapy alone (50.0%) and doublet chemotherapy alone (36.1%). Multivariate analysis identified low body mass index and presence of three or more metastatic sites as significant prognostic factors for PFS. This study is, to date, the largest real-world analysis of patients with BRAFV600E-mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients. The data highlight the intrinsic aggressiveness of this disease subgroup, confirming results from previous real-world studies and clinical trials, and stressing the urgent need for more effective treatment options in this setting." @default.
• W4308599711 created "2022-11-12" @default.
• W4308599711 creator A5006208754 @default.
• W4308599711 creator A5009868416 @default.
• W4308599711 creator A5013225646 @default.
• W4308599711 creator A5013525685 @default.
• W4308599711 creator A5015232096 @default.
• W4308599711 creator A5023168144 @default.
• W4308599711 creator A5039535296 @default.
• W4308599711 creator A5040688022 @default.
• W4308599711 creator A5059464854 @default.
• W4308599711 creator A5080476285 @default.
• W4308599711 creator A5080680994 @default.
• W4308599711 creator A5081985776 @default.
• W4308599711 creator A5083616708 @default.
• W4308599711 creator A5091592799 @default.
• W4308599711 creator A5039065081 @default.
• W4308599711 date "2022-12-01" @default.
• W4308599711 modified "2023-10-02" @default.
• W4308599711 title "Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study" @default.
• W4308599711 cites W1971211622 @default.
• W4308599711 cites W2101144899 @default.
• W4308599711 cites W2103789431 @default.
• W4308599711 cites W2112570485 @default.
• W4308599711 cites W2129998117 @default.
• W4308599711 cites W2131413118 @default.
• W4308599711 cites W2132598198 @default.
• W4308599711 cites W2134142320 @default.
• W4308599711 cites W2141172646 @default.
• W4308599711 cites W2152454229 @default.
• W4308599711 cites W2157137844 @default.
• W4308599711 cites W2159064822 @default.
• W4308599711 cites W2170226272 @default.
• W4308599711 cites W2470575266 @default.
• W4308599711 cites W2609927476 @default.
• W4308599711 cites W2739132742 @default.
• W4308599711 cites W2766421017 @default.
• W4308599711 cites W2791410762 @default.
• W4308599711 cites W2897087760 @default.
• W4308599711 cites W2944675676 @default.
• W4308599711 cites W2964997101 @default.
• W4308599711 cites W2977895282 @default.
• W4308599711 cites W3005488763 @default.
• W4308599711 cites W3007010344 @default.
• W4308599711 cites W3009139795 @default.
• W4308599711 cites W3031896647 @default.
• W4308599711 cites W3032658626 @default.
• W4308599711 cites W3037721034 @default.
• W4308599711 cites W3052790525 @default.
• W4308599711 cites W3093085210 @default.
• W4308599711 cites W3110528877 @default.
• W4308599711 cites W3119715349 @default.
• W4308599711 cites W3123642801 @default.
• W4308599711 cites W3128646645 @default.
• W4308599711 cites W3137959663 @default.
• W4308599711 cites W3139262736 @default.
• W4308599711 cites W3148370335 @default.
• W4308599711 cites W3169922422 @default.
• W4308599711 cites W3172680184 @default.
• W4308599711 cites W3178658200 @default.
• W4308599711 cites W4226337001 @default.
• W4308599711 cites W4243659722 @default.
• W4308599711 cites W4246064222 @default.
• W4308599711 cites W4293241248 @default.
• W4308599711 cites W4319877706 @default.
• W4308599711 doi "https://doi.org/10.1016/j.esmoop.2022.100603" @default.
• W4308599711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36368253" @default.
• W4308599711 hasPublicationYear "2022" @default.
• W4308599711 type Work @default.
• W4308599711 citedByCount "3" @default.
• W4308599711 countsByYear W43085997112022 @default.
• W4308599711 countsByYear W43085997112023 @default.
• W4308599711 crossrefType "journal-article" @default.
• W4308599711 hasAuthorship W4308599711A5006208754 @default.
• W4308599711 hasAuthorship W4308599711A5009868416 @default.
• W4308599711 hasAuthorship W4308599711A5013225646 @default.
• W4308599711 hasAuthorship W4308599711A5013525685 @default.
• W4308599711 hasAuthorship W4308599711A5015232096 @default.
• W4308599711 hasAuthorship W4308599711A5023168144 @default.
• W4308599711 hasAuthorship W4308599711A5039065081 @default.
• W4308599711 hasAuthorship W4308599711A5039535296 @default.
• W4308599711 hasAuthorship W4308599711A5040688022 @default.
• W4308599711 hasAuthorship W4308599711A5059464854 @default.
• W4308599711 hasAuthorship W4308599711A5080476285 @default.
• W4308599711 hasAuthorship W4308599711A5080680994 @default.
• W4308599711 hasAuthorship W4308599711A5081985776 @default.
• W4308599711 hasAuthorship W4308599711A5083616708 @default.
• W4308599711 hasAuthorship W4308599711A5091592799 @default.
• W4308599711 hasBestOaLocation W43085997112 @default.
• W4308599711 hasConcept C121608353 @default.
• W4308599711 hasConcept C126322002 @default.
• W4308599711 hasConcept C143998085 @default.
• W4308599711 hasConcept C2776694085 @default.
• W4308599711 hasConcept C2777802072 @default.
• W4308599711 hasConcept C2778260052 @default.
• W4308599711 hasConcept C2780962732 @default.
• W4308599711 hasConcept C2781230642 @default.
• W4308599711 hasConcept C526805850 @default.

• next